Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Tarsus Pharmaceuticals, Inc. (TARS) had Revenue of $182.95M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$182.95M
Net Income	$-115.55M
Cost of Goods Sold	$12.83M
Gross Profit	$170.13M
Operating Expenses	$303.52M
Operating Income	$-120.57M
Non-Operating Income/Expense	$5.01M
Pre-Tax Income	$-115.55M
Normalized Pre-Tax Income	$-115.55M
Income after Taxes	$-115.55M
Income from Continuous Operations	$-115.55M
Consolidated Net Income/Loss	$-115.55M
Normalized Income after Taxes	$-115.55M
EBIT	$-120.57M
EBITDA	$-123.08M
Weighted-Average Shares Outstanding (Basic)	37.60M
Weighted-Average Shares Outstanding (Diluted)	37.60M
Earnings per Share (EPS) (Basic)	$-3.07
Earnings per Share (EPS) (Diluted)	$-3.07
Balance Sheet Financials
Current Assets	$356.70M
Property, Plant, and Equipment	$2.31M
Long-Term Assets	$20.29M
Total Assets	$376.99M
Current Liabilities	$80.61M
Long-Term Debt	$71.84M
Long-Term Liabilities	$71.84M
Total Liabilities	$152.46M
Common Equity	$224.53M
Tangible Shareholders Equity	$216.21M
Shareholders Equity	$224.53M
Common Shares Outstanding	38.35M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-83.03M
Cash Flow from Investing Activities	$-199.19M
Cash Flow from Financial Activities	$154.66M
Beginning Cash	$224.95M
End Cash	$97.38M
Increase/Decrease in Cash	$-127.57M
Stock-Based Compensation	$27.82M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.42
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.24
Debt to Equity Ratio	0.32
Gross Margin	92.99%
Operating Margin	-65.90%
EBIT Margin	-65.90%
EBITDA Margin	-67.27%
Pre-Tax Profit Margin	-63.16%
Profit Margin	-63.16%
Free Cash Flow	$-84.59M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.49
Inventory Turnover	4.90
Receiveable Turnover	3.81
Days Sales in Receivables	95.88
Return on Equity	-51.46%
Return on Tangible Equity	-53.45%
Return on Assets	-30.65%
Return on Investments	-38.99%
Book Value Per Share	$5.85
Free Cash Flow per Share	$-2.25
Operating Cash Flow per Share	$-2.21

Data from Zacks Investment Research, Inc.